AstraZeneca plc (AZN) Raises Dividend to GBX 133.60 Per Share
AstraZeneca plc (LON:AZN) announced a dividend on Friday, February 2nd, Upcoming.Co.Uk reports. Shareholders of record on Thursday, February 15th will be paid a dividend of GBX 133.60 ($1.85) per share by the biopharmaceutical company on Monday, March 19th. This represents a yield of 2.8%. The ex-dividend date of this dividend is Thursday, February 15th. This is an increase from AstraZeneca’s previous dividend of $68.90. The official announcement can be viewed at this link.
Shares of AstraZeneca (LON:AZN) traded down GBX 8.50 ($0.12) during trading on Wednesday, reaching GBX 4,822 ($66.62). 752,141 shares of the company’s stock traded hands, compared to its average volume of 2,070,000. AstraZeneca has a 12-month low of GBX 4,260 ($58.86) and a 12-month high of GBX 5,520 ($76.26). The company has a market capitalization of $60,820.00 and a PE ratio of 2,819.88.
In other AstraZeneca news, insider Philip A. J. Broadley purchased 415 shares of the business’s stock in a transaction dated Friday, February 2nd. The stock was bought at an average cost of GBX 4,846 ($66.95) per share, for a total transaction of £20,110.90 ($27,785.16).
WARNING: “AstraZeneca plc (AZN) Raises Dividend to GBX 133.60 Per Share” was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this piece can be read at https://www.thecerbatgem.com/2018/02/14/astrazeneca-plc-azn-raises-dividend-to-gbx-133-60-per-share.html.
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.